Clinical Trial

A Study to Evaluate EDG-7500 in People With Renal Impairment

Completed Phase 1
View on ClinicalTrials.gov →
Summary
The purpose of this Phase 1 study is to understand and compare the amount of EDG-7500 in the blood after a single dose in participants with different levels of kidney function impairment versus participants with normal kidney function. The safety of EDG-7500 in participants with different levels of kidney function impairment will also be evaluated in this study.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-06-20; most recent amendment 2026-03-10.
Status change: Recruiting → Completed 2026-03-10
Trial Details
NCT Number NCT07034768
Lead Sponsor Edgewise Therapeutics, Inc.
Conditions Renal Impairments
Enrollment 37 participants
Start Date 2025-07-22
Primary Completion 2025-12-22 (estimated)
Study Completion 2025-12-26 (estimated)
Updated on ClinicalTrials.gov 2026-03-12